QuidelOrtho downgraded by Citigroup with a new price target
$QDEL
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Citigroup downgraded QuidelOrtho from Buy to Neutral and set a new price target of $72.00 from $95.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2025 | $44.00 | Hold → Buy | Jefferies |
| 12/11/2024 | $44.00 → $50.00 | Neutral → Buy | Citigroup |
| 12/10/2024 | $43.00 | Hold | Jefferies |
| 9/19/2024 | $42.00 → $50.00 | Neutral | UBS |
| 9/5/2024 | $40.00 → $57.00 | Hold → Buy | Craig Hallum |
| 3/4/2024 | $70.00 → $42.00 | Neutral → Sell | UBS |
| 2/14/2024 | $66.00 → $37.00 | Neutral → Underweight | JP Morgan |
| 12/11/2023 | $95.00 → $72.00 | Buy → Neutral | Citigroup |
8-K - QuidelOrtho Corp (0001906324) (Filer)
SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
8-K - QuidelOrtho Corp (0001906324) (Filer)
SAN DIEGO, Sept. 25, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ: QDEL), a global leader of in vitro diagnostics, has released the latest episode of its Science Bytes podcast, featuring Dr. Terry O'Neil, President and Medical Director of Urgent Care Pros. In Episode 51, Through the Shades of Illness, Testing Brings Clarity, Dr. O'Neil discusses how respiratory illnesses often present with overlapping symptoms, making it difficult to distinguish one condition from another without testing. Drawing on more than 20 years of emergency and urgent care experience, he explain
SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a leading global provider of innovative in vitro diagnostic technologies, is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs. The QUICKVUE Influenza + SARS Test is designed to deliver
SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025. The Company's fireside chat will begin at 3:10 p.m. ET / 12:10 p.m. PT. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00
Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously
Jefferies initiated coverage of QuidelOrtho with a rating of Hold and set a new price target of $43.00
SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal
Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T
Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi
SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)
― Labs revenue grew 4% as reported and 5% in constant currency ―― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024 ― ― Company reiterates full-year 2025 financial guidance ― Second Quarter 2025 Results(all comparisons are to the prior year period) Total revenue was $614 million, as reportedNon-respiratory revenue was $567 million, a decrease of 2% both as reported and in constant currency; excluding Donor Screening, non-respiratory revenue grew 1% in constant currencyLabs revenue grew 4% as reported and 5% in constant currencyImmunohematology revenue grew 4% as reported and 3% in constant currencyRespiratory
SAN DIEGO, July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2025 ended June 29, 2025, after the market close on Tuesday, August 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested
―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat